^
BIOMARKER:
BRCA2 mutation
i
Other names: BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
Entrez ID:
Related biomarkers:
BRCA2 mutation
Ovarian Cancer
BGB-290
Sensitive
:
A1
BeiGene Press Release - 5d
BRCA2 mutation
Peritoneal Cancer
BGB-290
Sensitive
:
A1
BeiGene Press Release - 5d
BRCA2 mutation
Fallopian Tube Cancer
BGB-290
Sensitive
:
A1
BeiGene Press Release - 5d
BRCA2 mutation
Prostate Cancer
nivolumab + ipilimumab
Sensitive
:
C4
AACR 2021 - 4wk
BRCA2 mutation
Triple Negative Breast Cancer
olaparib + palbociclib
Sensitive
:
D
J Exp Clin Cancer Res - 4wk
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
niraparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
niraparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
olaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
niraparib
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Breast Cancer
olaparib
Sensitive
:
A2
BRCA2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive
:
A2
BRCA2 mutation
Ovarian Cancer
bevacizumab
Resistant
:
A2
BRCA2 mutation
Breast Cancer
talazoparib
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our